Ultragenyx Pharmaceutical Files 8-K

TL;DR

UXAS filed an 8-K, no major news yet.

AI Summary

Ultragenyx Pharmaceutical Inc. filed an 8-K on April 2, 2026, reporting other events. The filing does not contain specific financial figures or new material agreements at this time.

Why It Matters

This filing indicates Ultragenyx is providing an update or disclosing information beyond routine quarterly reports, which could be significant for investors monitoring company developments.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any immediate financial risks or significant negative developments.

Key Players & Entities

• Ultragenyx Pharmaceutical Inc. (company) — Filer
• 0001515673 (company) — CIK
• 2026-04-02 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select

Filing Documents

• rare-20260402.htm (8-K) — 51KB
• 0001193125-26-139084.txt ( ) — 151KB
• rare-20260402.xsd (EX-101.SCH) — 23KB
• rare-20260402_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events On April 2, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the Company's resubmitted Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome Type A (MPS IIIA). The FDA set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8K contains forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipates," "expects," "plans," "continues," "will," "may," "potential," or other similar terms or expressions that concern the Company's expectations, plans, objectives, and intentions. Forwardlooking statements include, without limitation, statements related to the Company's expectations and projections, the development, regulatory status, review, timing and potential approval of UX111 (rebisufligene etisparvovec), including the anticipated PDUFA action date, the potential for accelerated approval, the outcome of the FDA's review of the resubmitted Biologics License Application (BLA), the timing and outcome of any regulatory inspections, the sufficiency of clinical, biomarker and long term follow up data to support regulatory approval, expectations regarding the safety, tolerability and durability of UX111, manufacturing readiness and capabilities, including at third party and company owned manufacturing facilities, and the potential availability and commercial launch of UX111. Such forward looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These risks and

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical Inc. Date: April 2, 2026 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy

View Full Filing

View this 8-K filing on SEC EDGAR